This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker Stock Might Rise From the Launch of Dimension Nexus AFM
by Zacks Equity Research
BRKR launches the Dimension Nexus AFM at the 2024 MRS Fall Meeting & Exhibit, expanding its Dimension AFM product line.
QGEN Stock Dips Despite Launch of Customized dPCR Assay Design Tools
by Zacks Equity Research
QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
New Alliances to Support STERIS Stock Despite Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
ABT Stock Benefits From First Patient Procedures With TAVI System
by Zacks Equity Research
Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures. This investigational TAVI system aims to offer best-in-class heart blood flow.
RMD vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
RMD vs. LMAT: Which Stock Is the Better Value Option?
International Expansion Supports BSX Stock Amid Macroeconomic Woes
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
by Zacks Equity Research
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval. The company plans a nationwide launch in the first quarter of 2025.
Zacks.com featured highlights include InterDigital, Greenbrier, Leidos, ResMed and Kontoor
by Zacks Equity Research
InterDigital, Greenbrier, Leidos, ResMed and Kontoor have been highlighted in this Screen of The Week article.
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
by Zacks Equity Research
The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.
5 Top-Ranked Dividend Growth Stocks for Your Portfolio
by Sweta Killa
Dividend investing is a popular choice among investors. It can provide a sense of security in times of market uncertainty or downturns.
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
by Zacks Equity Research
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.
Chemed Stock Hurt by Roto-Rooter Softness, Macro Issues Dent Growth
by Zacks Equity Research
The ongoing global economic conditions, such as general labor, supply chain and inflationary pressure, along with political and regulatory developments, are escalating expenses for CHE.
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
by Zacks Equity Research
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms.
MDT Stock Gains From FDA Approval for Its InPen App
by Zacks Equity Research
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus
by Zacks Equity Research
Henry Schein inked a new agreement to acquire Acentus to enhance its ability to deliver CGM products directly to patients' homes.
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Medical Stock Gains 37.9% Year to Date: What's Behind the Rally?
by Zacks Equity Research
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
by Zacks Equity Research
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
by Zacks Equity Research
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Here's Why You Should Add RMD Stock to Your Portfolio Now
by Zacks Equity Research
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Nevro Stock May Gain on the CE Mark Certification for HFX iQ
by Zacks Equity Research
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
by Zacks Equity Research
NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.